Sorafenib in patients with refractory or recurrent multiple myeloma

Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings

(2011) J. Beck et al.   ANNALS OF ONCOLOGY

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer

(2010) Martin Pölcher et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Experience with sorafenib and adverse event management

(2010) Joaquim Bellmunt et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06)

(2010) Joaquim Bellmunt et al.   LANCET ONCOLOGY

Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib

(2010) B. Vincenzi et al.   ONCOLOGIST

Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma

(2009) D. Hose et al.   BLOOD

Induction of angiogenesis by normal and malignant plasma cells

(2009) D. Hose et al.   BLOOD

Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study

(2009) Salvatore Del Prete et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs

(2009) V Ramakrishnan et al.   ONCOGENE

Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis

(2009) A Seckinger et al.   ONCOGENE

Clinical and biological significance of RAS mutations in multiple myeloma

(2008) W J Chng et al.   LEUKEMIA

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations

(2008) K S M Smalley et al.   ONCOGENE